Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the concordance of RAS mutation detection between the results obtained from circulating tumor DNA and those obtained with the "standard" method (testing from tumor tissue).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods | RAS mutations will be compared between tumor tissue (standard testing methods) and results obtained from circulating tumor DNA | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods in patients for whom circulating tumor DNA has been identified in the avalaible plasma sample. | RAS mutations will be compared between tumor tissue (standard testing methods) and results obtained from circulating tumor DNA. This subgroup of patients is defined as patients with at least one mutation identified in the panel of tested genes (Ion AmpliSeq Colon and Lung Cancer Panel) (RAS mutation or mutations on other genes TP53, PIK3CA, SMAD4 .... ) or with at least one methylated biomarker identified (for patients with no mutation identified in the panel of genes tested). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All treatment naive patients seen in consultation for metastatic colorectal cancer in the participating centers
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Baptiste Bachet, Dr | Contact | jean-baptiste.bachet@psl.aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Baptiste Bachet, Dr | Association des Gastro-entérologues Oncologues (AGEO) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Avicenne | Recruiting | Bobigny | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37390800 | Derived | Bachet JB, Laurent-Puig P, Meurisse A, Bouche O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Taieb J. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naive metastatic colorectal cancer. An AGEO prospective study. Eur J Cancer. 2023 Aug;189:112934. doi: 10.1016/j.ejca.2023.05.022. Epub 2023 Jun 7. | |
| 29438522 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood collection will be performed on the day of the first oncological consultation
| Baseline |
| Comparison of the timelines to obtain results between the two methods | Timelines to obtain RAS mutations will be compared between tumor tissue (standard testing methods) and circulating tumor DNA | Baseline |
| Comparisons of the costs between the two methods | Costs for the two methods will be compared between tumor tissue (standard testing methods) and circulating tumor DNA | Baseline |
| Hopital Béclère | Recruiting | Clamart | France |
|
| Hopital Henri Mondor | Recruiting | Créteil | France |
|
| Hopital Kremlin-Bicêtre | Recruiting | Le Kremlin-Bicêtre | France |
|
| CH Longjumeau et Sud | Recruiting | Longjumeau | France |
|
| Hopital Mermoz | Recruiting | Lyon | France |
|
| Hopital Cochin | Recruiting | Paris | France |
|
| Hopital Saint-Antoine | Recruiting | Paris | France |
|
| Hopital Saint-Louis | Recruiting | Paris | France |
|
| Hôpital Européen Georges Pompidou | Recruiting | Paris | France |
|
| Hôpital Pitié Salpêtrière | Recruiting | Paris | France |
|
| CHU Poitiers | Recruiting | Poitiers | France |
|
| CHU Robert Debré | Recruiting | Reims | France |
|
| Hôpital Trousseau | Recruiting | Tours | France |
|
| Derived |
| Bachet JB, Bouche O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061. |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |